| Model Number |
305U227 |
| Medical Device Problem Codes |
Incomplete Coaptation (2507); Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Codes |
Aortic Valve Insufficiency/ Regurgitation (4450); Insufficient Information (4580)
|
| Date of Event |
04/18/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
It was reported that the valve 305u227 mos aor cinchii ultra 27 experienced leaflet prolapse, valve performance issues/dysfunction, and poor coaptation of the valve leaflets.There was a planned treatment/intervention of the medtronic valve, although it was not scheduled.No patient complications have been reported as a result of this event.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
B1, b2, b5, h1 and imf (annex f) codes updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that 3 weeks later, a transcatheter valve was implanted valve-in-valve.No additional adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Sections updated: b.2 b.5 h.2 h.6 medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information reported the reason for intervention as severe aortic insufficiency.
|
| |
|
Search Alerts/Recalls
|